Introduction
Axl is a prototypical member of the receptor tyrosine kinase (RTK) Axl family, which is composed of Axl, Tyro3 (or Sky), and Mer. Two natural and highly homologous ligands for the Axl family are growth-arrest-specific gene 6 (Gas6) and protein S. 1 Axl has the highest affinity for Gas6 compared with other members of the Axl family, whereas protein S predominantly binds Tyro3 and Mer. 2 The Axl family of RTK has been known to be involved in a variety of biological functions, such as spermatogenesis, 3 phagocytic clearance of apoptotic cells, 4 inhibition of innate immune responses, 5 cell proliferation, 6 and survival. 1, 6 Axl has been reported to be overexpressed or activated in the vast majority of cancers, [7] [8] [9] including acute myeloid leukemia (AML). [10] [11] [12] Furthermore, a previous study revealed that high AXL levels associate with worse progression-free and overall survival of AML patients, 13 which suggests that Axl may be involved in the pathogenesis of AML. However, the mechanism(s) by which Axl contributes to AML has not been explored.
AML is characterized by abnormal proliferation and survival of myeloid progenitor and precursor cells and a premature block in myeloid differentiation.
14 A variety of genetic aberrations are associated with the occurrence of AML. [14] [15] [16] About 20% to 25% of AML patients harbor internal tandem duplication (ITD) mutations in the RTK Fms-like tyrosine kinase-3 (FLT3), which lead to constitutive phosphorylation of FLT3 and activation of its downstream signaling cascades, resulting ultimately in aberrant proliferation and survival. 14, 16, 17 FLT3-ITD mutations have been consistently found to be an adverse prognostic marker in these AML patients. 16 This has led to clinical trials treating FLT3-ITD 1 AML patients with small-molecule FLT3-selective tyrosine kinase inhibitors. 18 To date, however, FLT3 inhibitors used as a single agent or in combination with chemotherapy for FLT3-ITD 1 AML have not demonstrated improved clinical efficacy. 18 Because FLT3 can crosstalk with a network of various signaling pathways, 14, 16, 17, 19 identifying and analyzing the interplay of constitutively active FLT3 with aberrant signaling pathway(s) may lead to the identification of novel therapeutic target(s) for treatment of AML patients harboring constitutively active FLT3.
In human CD34 1 hematopoietic progenitor cells, Axl has been reported to be crucial for optimal signaling and biological activities of c-Kit, 20 which belongs to the same type III RTK family as FLT3. 16 This prompted us to hypothesize that Axl may also play a role in FLT3 signaling and thus in AML driven at least in part by constitutively activated FLT3 such as that found in FLT3-ITD 1 AML. In the present study, we provide evidence that supports a role for Axl in regulating the constitutive activation of FLT3 in FLT3-ITD 1 AML.
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Materials and methods
Cell culture, primary AML samples, and reagents
The MV4;11 human FLT3-ITD 1 AML cell line (ATCC, Manassas, VA) was cultured in RPMI1640 medium (Invitrogen, Grand Island, NY) supplemented with 10% fetal bovine serum and antibiotics and maintained at 37°C and 5% CO 2 . Thawed, viably cryopreserved primary leukemic blasts for the in vitro studies were previously obtained from FLT3-ITD 1 and FLT3-wild-type (WT) AML patients who provided written consent in accordance with the Declaration of Helsinki and with the approval from The Ohio State University Institutional Review Board. Human Control-Fc (CtrlFc) and Axl-Fc chimeric proteins used in the in vitro studies were purchased from R&D Systems (Minneapolis, MN) and were placed in cultures at a final concentration of 1 mg/mL. All antibodies used for flow cytometric analyses were purchased from BD Biosciences (San Diego, CA), unless otherwise noted. PKC412 and XL-880 were purchased from LC Laboratories (Woburn, MA) and Selleck Chemicals (Houston, TX), respectively.
RT-PCR
Total RNA was isolated from the cells treated as indicated in the figures by using RNeasy RNA isolation kit (QIAGEN, Germany).
Complementary DNA was generated using Moloney murine leukemia virus reverse transcriptase (Invitrogen) and was subject to polymerase chain reaction (PCR) with Taq DNA polymerase (Invitrogen). Primer sequences and PCR conditions for Axl, 10 Mer, 21 Gas6, 22 and protein S 23 were described previously. The mRNA levels for C/EBPa, 24 PU.1, 24 elastase 2, 25 myeloperoxidase, 25 and lysozyme 25 were measured by real-time reverse transcription PCR (RT-PCR) using SYBR-Green (Applied Biosystems, Foster City, CA). 18S rRNA was measured and used as a normalization control.
Immunoblotting and immunoprecipitation
To detect phospho-Axl, phospho-extracellular signal-regulated kinase (ERK), phospho-AKT, phospho-C/EBPa, C/EBPa, phospho-FLT3 (Tyr589/591), FLT3, and phospho-STAT5, cells were treated as described in the figure legends, lysed, and subjected to sodium dodecyl sulfate polyacrylamide gel electrophoresis followed by transfer to nitrocellulose membrane. The nitrocellulose membrane was then incubated with primary antibodies against proteins mentioned above (Cell Signaling, Danvers, MA), except antiphospho-STAT5 (BD Biosciences), followed by incubation with either anti-rabbit or anti-mouse secondary antibody conjugated with horseradish peroxidase (Santa Cruz Biotechnology). An enhanced chemiluminescence system (GE Healthcare, UK) was used for detection of proteins. Actin was used as a loading control. For immunoprecipitation, cells were lysed and the patients (P1 to P6) were subjected to immunoblot to detect phospho-Axl and Axl (top). Actin was used as a loading control. Peripheral blood mononuclear cells were obtained from a normal, healthy donor by Ficoll gradient centrifugation and were used as a negative control. Numbers under each row indicate the ratio of the intensity of each band (phospho-Axl or Axl) relative to that of the actin band. Cells from panel A were analyzed for surface expression of Axl by flow cytometry using an antibody against Axl (bottom). A nonreactive isotype antibody was used as a negative control. (B) AML blasts from 2 patients possessing FLT3-ITD mutations (P3 and P5) and from 3 patients harboring FLT3-WT (P7 to P9) were subjected to immunoblot to detect phospho-Axl and Axl. CD34
1 cells from a normal, healthy donor were used as a negative control. (C) AML blasts from 2 patients possessing FLT3-ITD mutations (P1 and P2) and from 3 patients harboring FLT3-WT (P7 to P9) were subjected to immunoblot to detect phospho-Axl, phospho-FLT3, and FLT3. PBMC, peripheral blood mononuclear cell.
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For personal use only. March 20, 2013. at Sistema Bibliotecario d'Ateneo -Università degli Studi di Bologna on bloodjournal.hematologylibrary.org From resulting supernatants were precleared by incubation with normal rabbit immunoglobulin G (IgG; Santa Cruz Biotechnology) for 1 hour at 4°C. After centrifugation, the supernatants were incubated with anti-Axl or anti-FLT3 rabbit antibody (Cell Signaling) at 4°C overnight, which was further incubated with Protein A-agarose beads (Santa Cruz Biotechnology) for 3 hours at 4°C. After centrifugation and washing at 4°C, protein-bead complexes were boiled and subjected to immunoblot analysis.
Measurement of cell proliferation and apoptosis
Viable cell numbers were counted with the trypan blue exclusion assay (Invitrogen). Detection of apoptosis was performed using the Annexin V : FITC Apoptosis Detection Kit I (BD Biosciences). After incubating the cells with fluorescein isothiocyanate (FITC)-conjugated annexin V and propidium iodide (PI) in the binding buffer for 15 minutes at room temperature, cells were analyzed using a flow cytometer (FACSCalibur, BD Biosciences).
Cell-cycle analysis
Cells were washed 3 times with phosphate-buffered saline (PBS), fixed with 70% methanol at 220°C for 24 hours, and incubated with RNase (20 mg/mL) and PI (50 mg/mL) for 30 minutes at room temperature. Cells were then subjected to flow cytometric analyses and the percentage of cells in each cell-cycle stage was calculated using FlowJo software (Version 7.2.5; Tree Star, Ashland, OR). NBT reduction assay for myeloid differentiation study
Nitroblue tetrazolium (NBT) reduction assay was performed as described previously. 26 Cells (10 5 cells per well) were treated with Ctrl-Fc or Axl-Fc for 4 days and then incubated for 30 minutes with medium containing NBT (1 mg/ mL) and phorbol myristate acetate (330 nM). Cells were then centrifuged and solubilized in dimethylsulfoxide and the absorbance at 570 nm was measured.
Axl gene expression knockdown using siRNA Cells were transfected with Ctrl (Santa Cruz Biotechnology, catalog number sc-108060) or Axl small interfering RNA (siRNA; Sigma, catalog number SIHK1049) using the Amaxa nucleofection technology (Amaxa, Germany) as described previously. 27 The Axl siRNA from Sigma is a mixture of 5 different (undisclosed) siRNAs targeting Axl. For personal use only. March 20, 2013. at Sistema Bibliotecario d'Ateneo -Università degli Studi di Bologna on bloodjournal.hematologylibrary.org From
Generation of Axl-Fc chimeric protein for in vivo mouse studies
Complementary DNA encompassing the extracellular domain (amino acids 1 to 442) of human Axl, which is the same as we used in in vitro studies, was generated by PCR and cloned into the pCR2.1 TA vector (Invitrogen). After enzymatic digestion with EcoRI (Invitrogen), a 1.3-kb fragment was cloned into the pFUSE mammalian expression vector (InvivoGen, San Diego, CA) containing human immunoglobulin G1 (IgG1) Fc fragment. The parental plasmid vector alone or the plasmid vector containing the extracellular domain of human Axl was transfected into 293T human embryonic kidney cell line using Profection Mammalian Transfection System (Promega, Madison, WI). The resulting fusion protein between the extracellular domain of human Axl and human IgG1 Fc fragment (Axl-Fc) was secreted into culture medium due to the presence of the interleukin-2 signal sequence on the plasmid vector. Supernatants from the cells transfected with the parental pFUSE vector contained only human IgG1 Fc, which was used as a Ctrl-Fc. Collected supernatants were applied to Melon gel chromatography cartridge (Pierce, Rockford, IL) and eluted. Ctrl-Fc or Axl-Fc chimeric proteins were kept frozen at 280°C until use.
Animal models for in vivo studies
All animal studies were performed according to protocols approved by the Institutional Animal Care and Use Committee and according to procedures of the University Laboratory Animal Resources at The Ohio State University. All animals were accommodated and maintained in a clean, sterile animal care facility.
Subcutaneous xenograft tumor model
Imprinting control region (ICR) severe combined immunodeficiency (SCID) mice were purchased from Taconic Farms (Hudson, NY) and maintained in the animal facility at The Ohio State University Comprehensive Cancer Center. Mice (about 6 weeks old) were injected subcutaneously with the MV4;11 human FLT3-ITD 1 AML cell line (5 3 10 6 cells per mouse), and 10 days later Ctrl-Fc or Axl-Fc (each 200 mg per mouse) was subcutaneously injected 3 times a week. PBS (100 ml per mouse) was also injected as a control. Four weeks later, tumor masses were excised from killed mice and weighed.
Leukemia engraftment model
ICR-SCID mice (about 4 to 6 weeks old; from Taconic Farms) were sublethally exposed to X-ray irradiator (200 cGy) 24 hours prior to intravenous injection of leukemic blasts from a cytogenetically normal (CN), FLT3-ITD 1 AML patient (2 3 10 7 cells per mouse). Four weeks after injection of leukemic cells, mice were treated with Ctrl-Fc or Axl-Fc (each 200 mg per mouse) by intraperitoneal injection 3 times a week for the following weeks. In some experiments, PKC412 (100 mg/kg of mouse) was orally administered into mice as described previously. 28 Peripheral blood was obtained from each mouse at 8 weeks after injection of primary leukemic blasts and the numbers of white blood cells (WBCs) were counted with Turk's solution (Carolina Biological Supply, Burlington, NC). For flow cytometry, red blood cells in peripheral blood from each mouse were removed by using Red Blood Cells lysis buffer (StemCell Technologies, Canada), and the prepared cell suspensions were stained with anti-human CD45 antibody and analyzed with a flow cytometer (FACSCalibur, BD Biosciences). Mice were killed when the animals became moribund. Bone marrow cell suspensions were obtained from each mouse as previously reported 29 and analyzed by flow cytometry to detect the leukemic cells using an anti-human CD45 antibody.
Statistical analyses
Data from in vitro and in vivo animal studies were analyzed using the Student t test. Estimated probabilities of survival were calculated using the Kaplan-Meier method, and the log-rank test evaluated differences between survival distributions in the in vivo mouse study.
Results
To investigate whether Axl is involved in the pathogenesis of AML, we first examined the status of Axl activation. Axl was constitutively phosphorylated to a variable degree in both the MV4;11 human FLT3-ITD 1 AML cell line (supplemental Figure 1B ) and in primary patient AML blasts taken prior to treatment in 6 patients with FLT3-ITD 1 AML and 3 patients with FLT3-WT AML (Figure 1A-B ; information about patients used in this study is described in supplemental Table 1 ). Axl was not constitutively phosphorylated in peripheral blood mononuclear cells ( Figure 1A ) or in CD34 1 hematopoietic progenitor cells ( Figure 1B ) from normal donors. We observed an association between the level of phosphorylated Axl and that of total Axl protein in AML patients ( Figure 1A ). However, we did not find such an association among the level of phosphorylated Axl, the expression of total Axl, and the mutational status of FLT3 ( Figure 1B ). That is, Axl was present and found to be constitutively phosphorylated in both FLT3-ITD 1 cases of AML that displayed phosphorylated FLT3 as well as in FLT3-WT AML patient samples without constitutively active FLT3 ( Figure 1C ). This suggests that phosphorylation of Axl is independent of FLT3 activation and could be important in the pathogenesis of FLT3-ITD 1 and FLT3-WT AML.
We next investigated whether Axl has a role in the proliferation and survival of AML cells. To study this, we used a soluble fusion protein (termed Axl-Fc) that consists of the extracellular domain of the Axl protein and the Fc portion of human IgG1. As a soluble We first looked to our earlier study in an attempt to identify the mechanism(s) by which Axl contributes to the pathogenesis of AML. We reported that Axl is necessary for maintaining activation of c-Kit, 20 which belongs to the same type III RTK family as FLT3. 31 Indeed, FLT3 inhibitors used in clinical trials have also been shown to inhibit c-Kit activity. 18 We thus hypothesized that FLT3 could be a potential target of Axl, at least in cases of FLT3- with Axl-Fc, the physical interaction between Axl and FLT3 was disrupted ( Figure 3C ), suggesting not only that Axl is a positive regulator of FLT3 phosphorylation but also that this regulation likely occurs through physical interaction between activated Axl and FLT3. To test the possibility that Axl-Fc was inhibiting the interaction between Axl and FLT3 by nonspecific binding to FLT3, anti-human IgG antibody was used to probe coimmunoprecipitated proteins pulled down by anti-FLT3 rabbit antibody. As seen in the second last row of Figure 3C (right), rabbit IgG was easily detected, but in the bottom row of the same figure human IgG, which is a part of Axl-Fc, was not detected. This indicates that Axl-Fc does not nonspecifically bind to FLT3 to interfere with the interaction between Axl and FLT3. The FLT3-ITD has previously been shown to contribute to an arrest in differentiation along the myeloid lineage, which is a characteristic hallmark of AML. 32 Because a block of Axl phosphorylation by Axl-Fc results in downregulation of FLT3-ITD phosphorylation (Figure 3) , we examined if treatment with Axl-Fc reversed the arrest of myeloid differentiation. Indeed, primary blasts from FLT3-ITD 1 AML patients treated with Axl-Fc in vitro exhibited (1) an increased surface density expression of CD11b, a myeloid lineage marker ( Figure 4A) ; (2) an increase in the number of cells capable of reducing NBT, which is a functional assay of myeloid differentiation measuring superoxide production ( Figure 4B ); (3) morphologic changes typical of being relieved from myeloid differentiation block (supplemental Figure 3B) ; and (4) significantly increased expression of genes known to be relevant to myeloid differentiation, such as myeloperoxidase, elastase 2, lysozyme, C/EBPa, and PU.1, in primary human FLT3-ITD 1 AML blasts ( Figure 4C ) and in the MV4;11 human FLT3- Figure 5A ). In addition, knockdown of Axl expression by siRNA induced apoptosis ( Figure 5B ) and increased the expression levels of the genes noted above to be augmented upon myeloid differentiation ( Figure 5C ). Collectively, these data confirm the results described above using Axl-Fc (Figures 3 and  4) and thus provide further support that activated Axl likely has a role in promoting proliferation, survival, and a block in differentiation of FLT3-ITD 1 AML cells.
To further explore the role of Axl in FLT3-ITD 1 AML in vivo,
we first employed a subcutaneous xenograft model. Axl-Fc administered 3 times per week for 4 weeks significantly suppressed 
Discussion
Our study showed that Axl is constitutively active in FLT3-ITD We also note that Axl likely has a role in FLT3-WT AML where FLT3 is not phosphorylated ( Figure 1C ). The fact that activated Axl does not have a role in phosphorylation of FLT3 in FLT3-WT AML makes it unlikely that activated Axl is serving as a primary kinase of FLT3 in FLT3-ITD 1 AML. Rather, it could be the case that activated
Axl interacts physically with FLT3-ITD following the latter's autophosphorylation ( Figure 3 36 have shown that WT FLT3, like its mutated form, is often constitutively activated (8 of 12 primary AML samples and 4 of 13 leukemia cell lines in their study) due to autocrine activation by overexpressed FLT3 ligand (FL). This raises the possibility that Axl might bind to phosphorylated FLT3 and contribute to the maintenance of its activated state in some FLT3-WT AML cases.
As noted above, we found Axl to be activated in FLT3-WT AML cells without constitutively active FLT3, and Axl-Fc and the pharmacologic Axl inhibitor XL-880 were each able to inhibit cell growth and induce apoptosis of FLT3-WT AML cells (Figure 2 ). This suggests that the antileukemic effects of Axl blockade are not exclusive to FLT3-ITD 1 AML and that Axl may contribute to leukemogenesis in this molecularly heterogeneous group of AML cases via other pathway(s). Although it remains to be investigated as to how Axl may be involved in such cases, previous studies may provide some insights. Ghosh and et al 37 demonstrated that Axl is constitutively active in B-cell chronic lymphocytic leukemia (CLL) and acts as a docking site of nonreceptor kinases, such as Syk and phosphoinositide-3 kinase. They also showed that a specific inhibitor of Axl, R428, could induce apoptosis of B-cell CLL. In addition, the study by Hahn and colleagues 38 revealed that Syk is constitutively active in FLT3-WT AML blasts and that a pharmacologic inhibitor of Syk could reduce leukemia burden in vivo. Taken together, these previous data suggest the possibility that Axl might be involved in the pathogenesis of FLT3-WT AML through its regulation of Syk and/or possibly other signaling pathways.
We have shown that blocking the activation of Axl with an excess of soluble Axl-Fc reduced FLT3-ITD 1 leukemia burden in vivo, thereby providing the rationale that Axl may have potential as a therapeutic target in FLT3-ITD 1 AML. Indeed, smallmolecule Axl inhibitors are already in preclinical and clinical development as targeted therapeutics against multiple types of tumors. Foretinib (GSK1363089), an orally available multikinase inhibitor of Axl, c-Met, and vascular endothelial growth factor receptor, has been tested against solid tumors in a phase 1 clinical trial 39 and has also been shown to be effective in a mouse lung cancer model. 40 Another Axl inhibitor, R428, blocked tumor spread and prolonged survival in mouse models of metastatic breast cancer 41 and could induce apoptosis of B-cell CLL in vitro. 37 Our data suggest that it would be worthwhile to test whether these Axl inhibitors, alone or in combination with other molecular-targeting compounds or chemotherapy, can improve the outcome of FLT3-ITD 1 AML patients.
In summary, our study introduces Axl as a regulator of constitutive FLT3 phosphorylation in FLT3-ITD 1 AML and as a potential therapeutic target for treating FLT3-ITD 1 AML patients. Its ability to target aberrant proliferation, survival, and a blockade in myeloid differentiation may make inhibitors of Axl useful alone or in combination with chemotherapy for FLT3-ITD 1 AML. Future studies may expand its role in a broader spectrum of AML.
